Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 26Rectal Neoplasms 8Colonic Neoplasms 8Stomach Neoplasms 2Pancreatic Neoplasms 1Metastatic Gastric Adenocarcinoma 1Gastric and Gastroesophageal Junction Adenocarcinoma 1Gastric Cancer Adenocarcinoma Metastatic 1Gastric Adenocarcinoma 1Gallbladder Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1Bile Duct Neoplasms 1Advanced Gastric Cancer 1

Interventions

camrelizumab 2apatinib 2trifluridine tipiracil drug combination 1tipiracil 1irinotecan sucrosofate 1Trifluridine 1S 1 (combination) 1Ramucirumab 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Metastatic Gastric Adenocarcinoma × Trifluridine × Clear all
NCT05927857 2026-04-09

Ramucirumab (Cyramza), Nal-IRI (ONIVYDE) and Trifluridine/Tipiracil (Lonsurf) in Second Line Metastatic Gastric Cancer .

National Health Research Institutes, Taiwan

Phase 1/2 Recruiting
45 enrolled
Gastrointestinal

Metastatic Gastric Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡